Overview

  • Product nameAnti-CSRP3 antibody
    See all CSRP3 primary antibodies
  • Description
    Mouse monoclonal to CSRP3
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant fragment: SPKPARSVTT SNPSKFTAKF GESEKCPRCG KSVYAAEKVM GGGKPWHKTC FRCAICGKSL ESTNVTDKDG ELYCKVCYAK NFGPTGIGFG GLTQQVEKKE , corresponding to amino acids 95-195 of Human CSRP3

Properties

Applications

Our Abpromise guarantee covers the use of ab56368 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notesWB: Use at a concentration of 1-5 µg/ml.

    This antibody has only been tested in WB against the recombinant fragment used as immunogen. We have no data on the detection of endogenous protein.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionPositive regulator of myogenesis. Plays a crucial and specific role in the organization of cytosolic structures in cardiomyocytes. Could play a role in mechanical stretch sensing. May be a scaffold protein that promotes the assembly of interacting proteins at Z-line structures. It is essential for calcineurin anchorage to the Z line. Required for stress-induced calcineurin-NFAT activation.
    • Tissue specificityCardiac and slow-twitch skeletal muscles.
    • Involvement in diseaseDefects in CSRP3 are the cause of cardiomyopathy dilated type 1M (CMD1M) [MIM:607482]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
      Defects in CSRP3 are the cause of cardiomyopathy familial hypertrophic type 12 (CMH12) [MIM:612124]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    • Sequence similaritiesContains 2 LIM zinc-binding domains.
    • Cellular localizationNucleus. Cytoplasm. Cytoplasm > cytoskeleton. Cytoplasm > myofibril > sarcomere > Z line. Mainly cytoplasmic (By similarity). In the nucleus it associates with the actin cytoskeleton (Potential). In the Z line, found associated with GLRX3.
    • Information by UniProt
    • Database links
    • Alternative names
      • cardiac antibody
      • Cardiac LIM protein antibody
      • CLP antibody
      • CMD1M antibody
      • CMH12 antibody
      • CRP3 antibody
      • Csrp3 antibody
      • CSRP3_HUMAN antibody
      • Cysteine and glycine-rich protein 3 antibody
      • Cysteine rich protein 3 antibody
      • Cysteine-rich protein 3 antibody
      • LIM domain only 4 antibody
      • LIM domain protein antibody
      • LMO4 antibody
      • MLP antibody
      • Muscle LIM protein antibody
      see all

    Anti-CSRP3 antibody images

    • Western blot against tagged recombinant protein immunogen using ab56368 CSRP3 antibody at 1ug/ml. Predicted band size of immunogen is 37 kDa

    References for Anti-CSRP3 antibody (ab56368)

    This product has been referenced in:
    • McCully JD  et al. Transcriptomic and proteomic analysis of global ischemia and cardioprotection in the rabbit heart. Physiol Genomics 38:125-37 (2009). WB ; Rabbit . Read more (PubMed: 19454556) »

    See 1 Publication for this product

    Product Wall

    There are currently no Abreviews or Questions for ab56368.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"